Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom improvement
RCT	200 people with plaque psoriasis affecting 5%–20% of body surface	Global clinical improvement 12 weeks with tazarotene 0.1% plus high- or mid-potency corticosteroid with tazarotene alone Absolute results not reported	Combination reported as significantly better than tazarotene alone P value not reported	Effect size not calculated	tazarotene plus mid-potency corticosteroids
RCT 4-armed trial	300 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks 95% with tazarotene plus high-potency corticosteroid 80% with tazarotene plus placebo	P <0.05 for tazarotene plus high-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus high-potency corticosteroid
RCT 4-armed trial	300 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks 91% with tazarotene plus medium-potency corticosteroid 80% with tazarotene plus placebo	P <0.05 for tazarotene plus medium-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus medium-potency corticosteroid
RCT 4-armed trial	300 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks with tazarotene plus low-potency corticosteroid 80% with tazarotene plus placebo Absolute results not reported	Reported as no significant difference between tazarotene plus low-potency corticosteroid v tazarotene plus placebo		Not significant
RCT 4-armed trial	398 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks 75% with tazarotene plus high-potency corticosteroid 54% with tazarotene plus placebo	P <0.05 for tazarotene plus high-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus high-potency corticosteroid
RCT 4-armed trial	398 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks 55% with tazarotene plus medium-potency corticosteroids 54% with tazarotene plus placebo
RCT 4-armed trial	398 people with plaque psoriasis covering at least 20% of body surface	Treatment success (at least 50% global improvement in appearance of lesions) at 12 weeks with tazarotene plus low-potency corticosteroids 54% with tazarotene plus placebo	Reported as not significant for tazarotene plus low-potency corticosteroids v tazarotene plus placebo		Not significant
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Plaque elevation (graded in a 9-point scale, from 0 = none to 8 = very severe) after 2–12 weeks' treatment with tazarotene 0.1% gel plus placebo cream with tazarotene 0.1% gel plus low-potency corticosteroid cream with tazarotene 0.1% gel plus medium-potency corticosteroid cream with tazarotene 0.1% gel plus high-potency corticosteroid cream Absolute results reported graphically	Reported as no significant difference between groups P value not reported		Not significant
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Plaque elevation (graded in a 9-point scale, from 0 = none to 8 = very severe) 4 weeks after treatment finished with tazarotene 0.1% gel plus placebo cream with tazarotene 0.1% gel plus low-potency corticosteroid cream with tazarotene 0.1% gel plus medium-potency corticosteroid cream with tazarotene 0.1% gel plus high-potency corticosteroid cream Absolute results reported graphically	Reported as no significant difference between groups P value not reported		Not significant
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3 2 weeks 42% with tazarotene 0.1% gel plus placebo cream 49% with tazarotene 0.1% gel plus low-potency corticosteroid cream Absolute numbers not reported	P reported as not significant for tazarotene plus low-potency corticosteroids v tazarotene plus placebo		Not significant
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3 2 weeks 42% with tazarotene 0.1% gel plus placebo cream 73% with tazarotene 0.1% gel plus medium-potency corticosteroid cream Absolute numbers not reported	P <0.05 for tazarotene plus medium-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus medium-potency corticosteroid
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3 2 weeks 42% with tazarotene 0.1% gel plus placebo cream 58% with tazarotene 0.1% gel plus high-potency corticosteroid cream Absolute numbers not reported	P <0.05 for tazarotene plus high-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus high-potency corticosteroids
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3* 12 weeks 80% with tazarotene 0.1% gel plus placebo cream 79% with tazarotene 0.1% gel plus low-potency corticosteroid cream Absolute numbers not reported	Reported as no significant difference between tazarotene plus low-potency corticosteroid v tazarotene plus placebo		Not significant
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3* 12 weeks 80% with tazarotene 0.1% gel plus placebo cream 91% with tazarotene 0.1% gel plus medium-potency corticosteroid cream Absolute numbers not reported	P <0.05 for tazarotene plus medium-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus medium-potency corticosteroid
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3* 12 weeks 80% with tazarotene 0.1% gel plus placebo cream 95% with tazarotene 0.1% gel plus high-potency corticosteroid cream Absolute numbers not reported	P <0.05 for tazarotene plus high-potency corticosteroid v tazarotene plus placebo	Effect size not calculated	tazarotene plus high-potency corticosteroid
RCT 4-armed trial	300 people with stable mild to moderate plaque psoriasis	Percentage of people with global treatment response score between 0 and 3* 4 weeks after end of treatment with tazarotene 0.1% gel plus placebo cream with tazarotene 0.1% gel plus low-potency corticosteroid cream with tazarotene 0.1% gel plus medium-potency corticosteroid cream with tazarotene 0.1% gel plus high-potency corticosteroid cream Absolute results reported graphically	Reported as no significant difference among groups P value not reported		Not significant